Search details
1.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1): 43-69, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38394770
2.
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(10): 1385-1415, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-33022644
3.
Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
Br J Haematol
; 183(5): 747-754, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30407619
4.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
; 18(1): 359, 2018 04 02.
Article
in English
| MEDLINE | ID: mdl-29609532
5.
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(9): 1108-1135, 2018 09.
Article
in English
| MEDLINE | ID: mdl-30181422
6.
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
J Natl Compr Canc Netw
; 16(3): 245-254, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29523663
7.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(5): 608-638, 2017 05.
Article
in English
| MEDLINE | ID: mdl-28476741
8.
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(7): 926-957, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28687581
9.
Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 111(52): 18679-84, 2014 Dec 30.
Article
in English
| MEDLINE | ID: mdl-25512507
10.
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
J Natl Compr Canc Netw
; 14(12): 1505-1512, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27956535
11.
Hodgkin lymphoma, version 2.2015.
J Natl Compr Canc Netw
; 13(5): 554-86, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25964641
12.
Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
Br J Haematol
; 184(4): 647-650, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29468651
13.
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
Blood
; 120(2): 249-58, 2012 Jul 12.
Article
in English
| MEDLINE | ID: mdl-22529287
14.
Chronic myelogenous leukemia, version 1.2015.
J Natl Compr Canc Netw
; 12(11): 1590-610, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25361806
15.
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Leukemia
; 38(1): 45-57, 2024 01.
Article
in English
| MEDLINE | ID: mdl-38017103
16.
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
Blood
; 118(15): 4150-8, 2011 Oct 13.
Article
in English
| MEDLINE | ID: mdl-21844565
17.
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
Blood
; 118(26): 6920-9, 2011 Dec 22.
Article
in English
| MEDLINE | ID: mdl-22031865
18.
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Cancer Invest
; 31(3): 172-6, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23406188
19.
Acute myeloid leukemia, version 2.2013.
J Natl Compr Canc Netw
; 11(9): 1047-55, 2013 Sep 01.
Article
in English
| MEDLINE | ID: mdl-24029121
20.
Chronic Myelogenous Leukemia, Version 1.2014.
J Natl Compr Canc Netw
; 11(11): 1327-40, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-24225967